Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation.
about
p53 Activation following Rift Valley fever virus infection contributes to cell death and viral productionA Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Confers Full Protection against Rift Valley Fever Challenge in SheepTemperature-sensitive mutations for live-attenuated Rift Valley fever vaccines: implications from other RNA virusesViruses and antiviral immunity in DrosophilaChemotactic and inflammatory responses in the liver and brain are associated with pathogenesis of Rift Valley fever virus infection in the mouseThree-Dimensional Organization of Rift Valley Fever Virus Revealed by Cryoelectron TomographyRNA polymerase I-mediated expression of viral RNA for the rescue of infectious virulent and avirulent Rift Valley fever virusesRandomized controlled field trial to assess the immunogenicity and safety of rift valley fever clone 13 vaccine in livestockMapping of transcription termination within the S segment of SFTS phlebovirus facilitated the generation of NSs-deletant viruses.Multi-faceted proteomic characterization of host protein complement of Rift Valley fever virus virions and identification of specific heat shock proteins, including HSP90, as important viral host factorsA replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challengeRift valley fever virus infection of human cells and insect hosts is promoted by protein kinase C epsilon.Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and preventionAttenuation of Chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein.The use of NanoTrap particles as a sample enrichment method to enhance the detection of Rift Valley Fever VirusA fusion-inhibiting peptide against Rift Valley fever virus inhibits multiple, diverse viruses.The consequences of reconfiguring the ambisense S genome segment of Rift Valley fever virus on viral replication in mammalian and mosquito cells and for genome packaging.Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in miceEvaluation of the Efficacy, Potential for Vector Transmission, and Duration of Immunity of MP-12, an Attenuated Rift Valley Fever Virus Vaccine Candidate, in Sheep.The dominant-negative inhibition of double-stranded RNA-dependent protein kinase PKR increases the efficacy of Rift Valley fever virus MP-12 vaccine.Rift Valley fever virus strain MP-12 enters mammalian host cells via caveola-mediated endocytosis.Genetic subpopulations of Rift Valley fever virus strains ZH548 and MP-12 and recombinant MP-12 strainsRift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates.Toscana virus NSs protein promotes degradation of double-stranded RNA-dependent protein kinase.A genome-wide RNAi screen reveals that mRNA decapping restricts bunyaviral replication by limiting the pools of Dcp2-accessible targets for cap-snatchingCharacterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs.Rift valley fever vaccines.Non-structural proteins of arthropod-borne bunyaviruses: roles and functions.Altered mitochondrial dynamics as a consequence of Venezuelan Equine encephalitis virus infection.The S segment of rift valley fever phlebovirus (Bunyaviridae) carries determinants for attenuation and virulence in mice.Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSsAdaptation of Puumala hantavirus to cell culture is associated with point mutations in the coding region of the L segment and in the noncoding regions of the S segment.NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription.A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep.Virus-like particle-based countermeasures against Rift Valley fever virus.Rescue of infectious rift valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene.A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity.Rift Valley fever virus NSs mRNA is transcribed from an incoming anti-viral-sense S RNA segment.Current Status of Rift Valley Fever Vaccine Development.Rift Valley Fever Vaccine Development, Progress and Constraints.
P2860
Q24319790-54575D11-7284-4A5F-99FE-2AFA01DC3A33Q26315336-7446DBAE-D1AD-43A6-9927-2EF5EB0EFDFEQ26796199-5650A1D0-D769-4262-83CD-511A1A142EA4Q26998819-C6A979DC-7C6D-4E71-BA62-0766ABD3ED83Q27305612-E3132E77-BE8E-466F-85F8-65A10FE8E643Q27487138-D2FE1F39-CD95-4DB7-8039-814DD28F6362Q27487321-B408A3FD-7921-49F0-927D-EC09BCE30AAFQ28652554-BA0167A8-F8CC-4EEC-B7D8-09069F70F93DQ33442499-809B0050-EEEE-4B62-B611-CBE0BC82E5B2Q33583806-062864D8-48E1-4A60-B13C-CFAB1104D253Q33621078-01B2A64D-DCA5-4B67-BBD1-E22A9CB43357Q33760778-0E5DA5BE-730C-4AE2-AF48-42148CB27A58Q33960690-B956B39D-6E6B-4A68-9FEB-81D7AED7E365Q34264257-B8FD5E66-AFEC-4E35-8621-AFD234CE5A2CQ34828833-B95BF9FD-E8AD-4595-AAD6-3DE24AB38FB5Q34999859-4B590C6F-1769-4A0A-9DA4-4182577EF5D5Q35097103-9604D830-6CC2-4D38-A51E-2560A24078CFQ35202797-39B67C5D-64F1-4F27-8AD5-32F8DB4B1453Q35902010-111D89E2-0792-4E00-8669-68124E6E47F9Q36155392-550903B6-60D8-4F2E-AFDB-C3CC3720AB06Q36397378-C687D116-1284-4E74-9AB2-FAE5151DA41FQ36414512-FA7A6419-31BD-4DD9-9F95-8B7883CE7AB3Q36514844-5AA2B631-3180-48DC-8B8F-00FA0B882E77Q36759758-504DCAE8-E6CF-4DF7-9AA7-592E0652B3CFQ37019225-8B752AC7-A45F-4A9B-ADF8-144F8BDB1088Q37087027-11E86A1F-EDCD-43DF-BA9F-3613F3DD89D7Q37393780-EA4ACF1F-01D7-497A-9C91-C714F46DA116Q38150190-6DCC98EC-F23F-473C-BE37-5F9866DFED65Q39027481-D8C5B684-A930-4ED5-8BBB-A74D24ED4F75Q39588385-CA81F755-1611-44DE-851C-AAC4878B51EAQ39601913-DE0C744C-B8D1-46B0-B7CF-EE789BA88F48Q39796666-1B4237D0-6F1A-4D8E-A558-BF511B564F96Q39960501-7F696C31-01E5-482D-9E65-2BC66E98E000Q40186455-819480B4-6272-42BF-ABBF-EEE51094C23CQ40254473-2794DC1D-CC1C-4A20-AAEC-9D56C011C6E2Q40311587-CD561876-DB1C-4DB7-81AE-FA70314E3666Q40379142-642744A7-9EE2-43D2-A9FC-A267772F62E6Q40499504-10EB8C2B-E032-4964-8C83-E0576F5459F9Q41929716-7ECF2578-CD8A-459C-8CF6-A2C185D5AFA2Q42553036-EDAF0C72-2655-4D36-B300-CEC6B3CF4483
P2860
Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Mapping of the mutations prese ...... putative role in attenuation.
@en
type
label
Mapping of the mutations prese ...... putative role in attenuation.
@en
prefLabel
Mapping of the mutations prese ...... putative role in attenuation.
@en
P2093
P1433
P1476
Mapping of the mutations prese ...... putative role in attenuation.
@en
P2093
P356
10.1016/S0168-1702(97)00097-X
P577
1997-11-01T00:00:00Z